Thus, transdermal treatment of LPPC/TAM might provide the breast cancer patients with CYP2D6 polymorphisms another efficient therapeutics and avoid the side effects of systemic treatment under tamoxifen administration. This evidence concerns the gene CYP2D6 and breast cancer.